Varanasi News Magazine

Progressive Familial Intrahepatic Cholestasis (PFIC) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

 Breaking News
  • No posts were found

Progressive Familial Intrahepatic Cholestasis (PFIC) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

July 31
20:37 2020
Progressive Familial Intrahepatic Cholestasis (PFIC) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

Delveinsight Business Research
DelveInsight’s “Progressive Familial Intrahepatic Cholestasis (PFIC) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Progressive Familial Intrahepatic Cholestasis (PFIC), historical and forecasted epidemiology as well as the Progressive Familial Intrahepatic Cholestasis (PFIC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

As per NIH, (PFIC) is a disorder that causes progressive liver disease, which typically leads to liver failure in which liver cells are unable to secrete a digestive fluid called bile. The buildup of bile in liver cells causes liver disease in affected individuals. The average age at onset is three months, although some patients do not develop jaundice until later, even as late as adolescence. PFIC can progress rapidly and cause cirrhosis during infancy or may progress relatively slowly with minimal scarring into adolescence. Few patients survive into the third decade of life without treatment.

The signs and symptoms for PFIC include short stature, deafness, diarrhea, and inflammation of the pancreas (pancreatitis), and low levels of fat-soluble vitamins (vitamins A, D, E, and K) in the blood. In addition to signs and symptoms related to liver disease, people with PFIC1 may have short stature, deafness, diarrhea, inflammation of the pancreas (pancreatitis), and low levels of fat-soluble vitamins (vitamins A, D, E, and K) in the blood. Affected individuals typically develop liver failure before adulthood. People with PFIC2 often develop liver failure within the first few years of life. Additionally, affected individuals are at increased risk of developing a type of liver cancer called hepatocellular carcinoma.

 

Get FREE sample copy at: 

https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market

 

progressive-familial-intrahepatic-cholestasis-pfic-market

 

The Progressive Familial Intrahepatic Cholestasis (PFIC) market report also covers emerging drugs, current treatment practices, Progressive Familial Intrahepatic Cholestasis (PFIC) market share of the individual therapies, current and forecasted Progressive Familial Intrahepatic Cholestasis (PFIC) Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Progressive Familial Intrahepatic Cholestasis (PFIC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 

 

Progressive Familial Intrahepatic Cholestasis (PFIC) Market Key Facts

PFIC is estimated to affect 1 in 50,000 to 100,000 people worldwide.

PFIC type 1 has been found to be much more common in certain populations of the United States.

As per the study conducted by Baker et al., in the United Kingdom, the incidence of intrahepatic cholestasis was 1 per 18,000 live births.

 

Key Benefits of Progressive Familial Intrahepatic Cholestasis (PFIC) Market Report

  • Progressive Familial Intrahepatic Cholestasis (PFIC) market report provides an in-depth analysis of Progressive Familial Intrahepatic Cholestasis (PFIC) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Progressive Familial Intrahepatic Cholestasis (PFIC) market report will help in developing business strategies by understanding the Progressive Familial Intrahepatic Cholestasis (PFIC) Market trends & developments, key players and future market competition that will shape and drive the Progressive Familial Intrahepatic Cholestasis (PFIC) market in the upcoming years.

  • The Progressive Familial Intrahepatic Cholestasis (PFIC) market report covers Progressive Familial Intrahepatic Cholestasis (PFIC) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Progressive Familial Intrahepatic Cholestasis (PFIC) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

 

Progressive Familial Intrahepatic Cholestasis (PFIC) Market

Currently, the market of PFIC does not hold any approved interventions but changes in the diet, medicines, and surgical treatments can reduce the effects and complications of the condition. The treatment, which is generally symptomatic involves observation of the expert physicians depending on the features and severity of the condition and its effects.

The Progressive Familial Intrahepatic Cholestasis (PFIC) market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Progressive Familial Intrahepatic Cholestasis (PFIC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Progressive Familial Intrahepatic Cholestasis (PFIC) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

 

Progressive Familial Intrahepatic Cholestasis (PFIC) Epidemiology

The differential diagnoses of PFIC include Aagenes Syndrome, Alpha1-Antitrypsin (AAT) Deficiency, Arthrogryposis-Renal Dysfunction Cholestasis Syndrome, Autoimmune Hepatitis, Benign Recurrent Intrahepatic Cholestasis, Bile Acid Synthetic Disorder, Biliary Atresia Imaging, Choledochal Cysts, etc.

 

PFIC type 1 has been found to be much more common in certain populations of the United States.

The Progressive Familial Intrahepatic Cholestasis (PFIC) epidemiology section covers insights about historical and current Progressive Familial Intrahepatic Cholestasis (PFIC) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 

Progressive Familial Intrahepatic Cholestasis (PFIC) Drugs Uptake and Key Market Players

The Progressive Familial Intrahepatic Cholestasis (PFIC) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Familial Intrahepatic Cholestasis (PFIC) market or expected to get launched in the market during the study period. The analysis covers Progressive Familial Intrahepatic Cholestasis (PFIC) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The pipeline of PFIC is not robust. However, owing to the positive outcomes of some of the key players the PFIC market is expected to show a positive growth.

The key pharma players in the Progressive Familial Intrahepatic Cholestasis (PFIC) market includes:
Mirum Pharmaceuticals
Albireo
Vivet Therapeutics
And others.

Drugs Covered
Maralixibat (LUM001/ SHP625)
A4250 (Odevixibat)
VTX-802
VTX-803
And many others.

 

Table of Content

1. Key Insights

2. Executive Summary 

3. Progressive Familial Intrahepatic Cholestasis (PFIC) Competitive Intelligence Analysis

4. Progressive Familial Intrahepatic Cholestasis (PFIC) Market Overview at a Glance

5. Progressive Familial Intrahepatic Cholestasis (PFIC) Disease Background and Overview

6. Progressive Familial Intrahepatic Cholestasis (PFIC) Patient Journey

7. Progressive Familial Intrahepatic Cholestasis (PFIC) Epidemiology and Patient Population

8. Progressive Familial Intrahepatic Cholestasis (PFIC) Treatment Algorithm, Current Treatment, and Medical Practices

9. Progressive Familial Intrahepatic Cholestasis (PFIC) Unmet Needs

10. Key Endpoints of Progressive Familial Intrahepatic Cholestasis (PFIC) Treatment

11. Progressive Familial Intrahepatic Cholestasis (PFIC) Marketed Products

12. Progressive Familial Intrahepatic Cholestasis (PFIC) Emerging Therapies

13. Progressive Familial Intrahepatic Cholestasis (PFIC) Seven Major Market Analysis

14. Attribute Analysis

15. Progressive Familial Intrahepatic Cholestasis (PFIC) Market Outlook (7 major markets)

16. Progressive Familial Intrahepatic Cholestasis (PFIC) Access and Reimbursement Overview

17. KOL Views on the Progressive Familial Intrahepatic Cholestasis (PFIC) Market.

18. Progressive Familial Intrahepatic Cholestasis (PFIC) Market Drivers

19. Progressive Familial Intrahepatic Cholestasis (PFIC) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

Related Reports

Progressive Familial Intrahepatic Cholestasis (PFIC) Epidemiology Forecast to 2030

DelveInsight’s Progressive Familial Intrahepatic Cholestasis (PFIC) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Progressive Familial Intrahepatic Cholestasis (PFIC) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

Progressive Familial Intrahepatic Cholestasis (PFIC) Pipeline Insights, 2020

Progressive Familial Intrahepatic Cholestasis (PFIC) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Progressive Familial Intrahepatic Cholestasis (PFIC) market.

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/